Comparison of Dysport Reconstitution at 1.5 mL and 2.5 mL for the Treatment of Moderate to Severe Glabellar Lines

Five month, randomized, subject- and evaluator-blinded, multi-center, mult-visit study.
Subjects treated with Dysport following the US on-label guidelines.

Key Inclusion Criteria:

1. Botulinum toxin naïve subject (facial area)

2. Moderate to severe (GLSS = 2 or 3) glabellar lines at maximum frown and mild to severe
(GLSS = 1, 2, or 3) glabellar lines at rest using the validated 4-point Photographic
Scale, as assessed by the treating investigator and the blinded evaluator.

Key Exclusion Criteria:

1. Have known allergies or sensitivities to Dysport®, any of its excipients, or cow's
milk protein

2. Have rhytids of the glabellar region that cannot be smoothed out by manually spreading
the skin apart

3. Have a history or have signs and symptoms of eyelid or brow ptosis or signs of
compensatory frontalis muscle activity, as judged by the investigator

4. Have clinical or subclinical neuromuscular junctional disorders (eg, myasthenia
gravis, Lambert Eaton syndrome, or amyotrophic lateral sclerosis) or a history of
dysphagia or aspiration

5. Are women who are pregnant or breast-feeding or who intend to get pregnant within the
duration of the study

6. Have an active inflammation or infection in the areas to be treated or had any prior
surgery, tattoos, piercings, or scarring in the facial area that, in the opinion of
the investigator, may interfere with the results

7. Have had any previous insertion of any permanent or semi-permanent material,
hyaluronic acid, or collagen fillers in the glabellar region

8. Have any chronic or acute medical condition that, may pose a risk to the safety of the
subject, or may interfere with the assessment of safety or efficacy in this study